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Optic atrophy (OA) and sensorineural hearing loss (SNHL) are
key abnormalities in several syndromes, including the recessive-
ly inherited Wolfram syndrome, caused by mutations in WFS1.
In contrast, the association of autosomal dominant OA and
SNHL without other phenotypic abnormalities is rare, and
almost exclusively attributed to mutations in the Optic Atrophy-1
gene (OPA1), most commonly the p.R445H mutation. We pres-
ent eight probands and their families from the US, Sweden, and
UK with OA and SNHL, whom we analyzed for mutations in
OPA1 and WFS1. Among these families, we found three hetero-
zygous missense mutations in WFS1 segregating with OA and
SNHL: p.A684V (six families), and two novel mutations, p.G780S
and p.D797Y, all involving evolutionarily conserved amino acids
and absent from 298 control chromosomes. Importantly, none of
these families harbored the OPA1 p.R445H mutation. No mito-
chondrial DNA deletions were detected in muscle from one
p.A684V patient analyzed. Finally, wolframin p.A684V mutant
ectopically expressed in HEK cells showed reduced protein levels
compared to wild-type wolframin, strongly indicating that the
mutation is disease-causing. Our data support OA and SNHL
as a phenotype caused by dominant mutations in WFS1 in
these additional eight families. Importantly, our data provide
the first evidence that a single, recurrent mutation in WFS1,
p.A684V, may be a common cause of ADOA and SNHL, similar
to the role played by the p.R445H mutation in OPA1. Our
findings suggest that patients who are heterozygous for WFS1
missense mutations should be carefully clinically examined for
OA and other manifestations of Wolfram syndrome.
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INTRODUCTION
Optic atrophy (OA) and hearing impairment are features of
several syndromes such as X-linked Mohr–Tranebjaerg syndrome
(OMIM 304700, deafness–dystonia–optic neuronopathy
syndrome), X-linked Charcot–Marie–Tooth disease-5 (OMIM
311070, OA, deafness, and polyneuropathy), and Gustavson syn-
drome (OMIM 309555, X-linked mental retardation with OA,
deafness, and seizures). In addition, optic atrophy and deafness
are features of the Wolfram syndrome type 1 (OMIM 222300)
and 2 (OMIM 604928). In contrast, autosomal dominant OA
(ADOA) and sensorineural hearing loss (SNHL) without any other
phenotypic abnormality have been described in relatively few
families, with the first report referring to a Swedish family that
was clinically described in a Swedish Physician’s journal
[Samuelson, 1940], and re-investigated as one of the families
presented here.
Wolfram syndrome type 1 is a rare and severe autosomal
recessive neurodegenerative disease, characterized by diabetes
mellitus, optic atrophy, diabetes insipidus and deafness
(DIDMOAD) and is caused by mutations in the WFS1 gene
(reviewed in Tranebjaerg et al. [2009]). Additional clinical
features may include renal abnormalities, ataxia, dementia/mental
retardation, and diverse psychiatric illnesses. The minimal
diagnostic criteria for Wolfram syndrome are OA and diabetes
mellitus of juvenile onset. Hearing impairment in Wolfram
syndrome is typically progressive and mainly affects the higher
frequencies [Cryns et al., 2003], but a small fraction of affected
individuals have congenital deafness [Barrett et al., 1995; Hansen
et al., 2005]. Mutations in WFS1 are also a common cause of
isolated autosomal dominant low-frequency nonsyndromic
sensorineural hearing loss (LFSNHL) [Bespalova et al., 2001;
Young et al., 2001]. In addition, a WFS1 p.E864K missense
mutation has been reported in two families with dominantly
inherited deafness with some members being affected by OA
and impaired glucose regulation/diabetes [Eiberg et al., 2006;
Valero et al., 2008], thereby mimicking Wolfram syndrome,
but in an attenuated version. Finally, very recently, a p.K836N
mutation in WFS1 has been found associated with autosomal
dominant optic neuropathy and deafness in one family
[Hogewind et al., 2010]. No plausible functional explanation has
been found to explain the vast differences in clinical presentations
and patterns of inheritance.
So far, more than 140 recessive mutations causing
Wolfram syndrome have been identified. Most of these are
truncating mutations, mainly located in exon 8 and unique to
a particular individual or a few individuals/families. In the
dominantly inherited disease, LFSNHL, the WFS1 mutations
are mainly missense mutations in exon 8; 28 different missense
mutations have been identified (http://www.khri.med.umich.edu/
research/lesperance_lab/low_freq.php).
Until recently, only one gene, Optic Atrophy-1 (OPA1),
had been found to underlie isolated optic atrophy and hearing
loss. OPA1 encodes a dynamin-related GTPase involved in
mitochondrial biogenesis (OMIM 605290) and is the gene
most frequently underlying OA either isolated or in syndromic
form [Amati-Bonneau et al., 2009; Yu-Wai-Man et al., 2010].
One recurrent OPA1 mutation, the heterozygous p.R445H
missense mutation, underlies the majority of reported cases of
isolated OA and hearing loss. This mutation was first identified in
a Japanese and a French patient [Amati-Bonneau et al., 2003;
Shimizu et al., 2003].
In this study, we demonstrate that heterozygous WFS1 missense
mutations cause autosomal dominant isolated OA and hearing
loss in eight families. Importantly, our data also suggest that a
single, recurrent, non-founder WFS1 mutation, p.A684V, which
was identified in six of the eight families studied, may be a common
cause of isolated autosomal dominant OA and SNHL similar to
the p.R445H mutation in OPA1.
PATIENTS AND METHODS
Clinical Data
Eight families of Caucasian origin from the US, Sweden, and UK
diagnosed with OA and SNHL were included in this study (Fig. 1).
Initially, we analyzed 15 probands with OA and deafness in the
study, but only identified mutations in WFS1 in 8 of these probands,
and the families of these eight probands are described here in detail.
The clinical data were compiled from available medical records
from different hospitals. Venous blood was drawn from available
patients and relatives and DNA was extracted using standard
methods. The study was approved by the Danish Research Ethical
Committee (reference numbers KF 01-234/02 and KF 01-108/03)
and the Institutional Review Board (IRBMED) of the University
of Michigan Health System. When possible, patients underwent
audiometric and ophthalmological evaluations. Normal hearing
was defined as a pure tone average hearing level of less than or equal
to 20 dB. Mild hearing loss was defined as 21–40 dB HL, moderate
loss as 41–60 dB HL, severe loss as 61–90 dB HL, and profound
loss was defined as exceeding 90 dB HL. OA was evaluated based on
available ophthalmological examinations. Five of the families
(NSDF916, NSDF1272, NSDF1865, NSDF1793, and NSDF2032)
were ascertained through a study of genetic deafness in the alumni
of Gallaudet University (a university for the education of the deaf
and hard-of-hearing students, located in Washington, DC, USA)
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FIG. 1. Pedigrees of the eight families investigated in this study. All the families show a segregation pattern compatible with the conclusion that the
indicated WFS1 mutation causes autosomal dominant optic atrophy and hearing loss, except for family 81, where the father of two children with
Wolfram syndrome is a sporadic case. Probands are indicated by arrows. Black symbols indicate optic atrophy with hearing loss patients. Black
shading on the left part of symbol indicates individuals with isolated hearing loss and on the right part individuals with isolated optic atrophy. The
WFS1 molecular result is indicated below individuals from whom DNA samples were available. N¼ normal allele. The presence of GJB2 mutation are
indicated (c.35delG or p.M34T).
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[Arnos et al., 2008] and the North American Repository of deaf
individuals [Pandya et al., 2003].
Sequence Analysis
Prior to WFS1 sequence analysis, GJB2 sequencing was performed
in all probands and mutations were ruled out as the genetic cause
of deafness in all but one proband, who had a complex family
history of deafness. Primers were as described in Eiberg et al. [2006]
or designed to PCR amplify exons and 20–50 bp of surrounding
intronic regions of WFS1, OPA1, TIMM8A (RefSeq NM_006005.2,
NM_015560.2 (OPA1 exons 1-28), NM_130837.2 (OPA1 exons
4B and 5B) and NM_004085.3, respectively). WFS1, OPA1 and
TIMM8A were sequenced in DNA samples from all probands.
WFS1 exon 8 contains several polymorphisms and to avoid using
primers annealing to a region with polymorphisms, which could
result in PCR amplification of only one allele, WFS1 exons 7 and 8
were amplified as one PCR product using the primers 5’-GCA-
GATCATGTTCGATGGAGCGGTTGGC-3’ and 5’-CCTCATGG-
CAACATGCACTGGAAGCTCC-3’, and AccuPrime Taq DNA
Polymerase High Fidelity (Invitrogen, Taastrup, Denmark) ampli-
fying a fragment of 7930 bp. Furthermore, exon 8 sequencing
primers were carefully positioned to avoid overlapping known
polymorphisms. Primer sequences and PCR conditions are avail-
able upon request. PCR products were sequenced using BigDye
Terminator chemistry (Applied Biosystems) and separated on an
ABI 3130XL genetic analyzer (Applied Biosystems) according to the
manufacturer’s instructions. Identified base pair changes were
checked against databases of published polymorphisms and muta-
tions (http://www.khri.med.umich.edu/research/lesperance_lab/
low_freq.php; http://www.hgmd.cf.ac.uk/ac/index.php). In order
to study the segregation of the mutations with the disease in each
family, we used direct sequencing of PCR amplified genomic DNA.
All detected mutations (Table I) were tested for their absence in 298
control chromosomes from 53 Danish and 96 UK ethnically
matched Caucasian control individuals (from Sigma Aldrich).
The evolutionary conservation of wolframin amino acids
among WFS1 orthologs was investigated using the ClustalW2
multiple sequence alignment program (http://www.ebi.ac.uk/
Tools/clustalw2/index.html) and the Boxshade 3.21 program
(hhtp://www.ch.embnet.org/software/BOX_form.html).
Haplotype Analysis
For haplotype analysis, five polymorphic dinucleotide repeat
DNA markers from the 4p16.2-p15.33 WFS1 genomic region
(Tel- D4S412, D4S3023, D4S431, D4S394, D4S403-Cen) were
used according to standard protocols (Table IS online). Infor-
mation about primer sequences and physical map positions were
obtained from UCSC Genome Browser Human Mar. 2006 (hg18)
assembly web site (http://genome.ucsc.edu/index.html?org¼Human).
An 18-bp extension sequence (50-TGACCGGCAGCAAAATTG-30)
was added to the 50 end of the forward primer to allow
amplification of a fluorescently labeled third primer for visualiza-
tion on an ABI 3130XL genetic analyzer [Mellersh et al., 2006].
Genotypes were scored semi-automatically using Genemapper
(Applied Biosystems) and the haplotypes were constructed
manually.
FIG. 1. (Continued)
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mtDNA Deletion Analysis
Total DNA was extracted from skeletal muscle using QIAamp
DNA Mini Kit (Qiagen). Aliquots of 0.1 mg DNA were digested
with the restriction enzyme PvuII (New England Biolabs) and
fractionated by electrophoresis in 0.5% agarose gels. The DNA
was then transferred to Hybond-C nitrocellulose filter (GE
Healthcare) by capillary blotting under standard procedures. The
filter was hybridized with an equimolar mix of radiolabeled mtDNA
probes corresponding to nucleotides 1-12640 and 14956-16569,
as described previously [Larsson et al., 1990]. Hyperfilm MP (GE
Healthcare) was exposed to the filter for 4 hr before development.
Protein Expression Analysis of Wolframin Mutants
Expression vector for wild-type, myc epitope-tagged wolframin
was kindly provided by Dr. Timothy G. Barrett, UK. Mutations
were introduced in wolframin using the QuickChange procedure
(Stratagene) and confirmed by sequencing. Each mutant was
generated three independent times and subjected to protein
expression analysis. HEK293 cells were cultured and transfected
as described [Doehn et al., 2009]. Briefly, 1.6 105 cells were seeded
per 3.1 cm2 dish and co-transfected the following day, using 0.5 mg
of wolframin and enhanced green-fluorescent protein (EGFP)
expression plasmid, respectively, complexed with 3 ml FuGENE
6 reagent (Roche), according to the manufacturer’s instructions.
After 16 hr, the cells were lysed with SDS-PAGE sample buffer (2%
sodium dodecyl sulfate, 62 mM Tris-HCL (pH 6.8), 10% glycerol,
50 mM dithiothreitol, 0.12% bromophenol blue). Aliquots of the
cell lysates were subjected to SDS-PAGE and immunoblotting
analysis with antibody against the myc-tag on wolframin or
EGFP, using standard immunoblotting procedures.
RESULTS
Families
The pedigrees of the eight families studied here all present autoso-
mal dominant OA and SNHL and are shown in Figure 1. Clinical
and genetic findings are summarized in Tables I–III. None of the
probands contained the OPA1 mutations p.R445H or p.G439V nor
any other mutations in the entire OPA1 or TIMM8A genes that
might cause disease (a single silent OPA1 variant, p.R393R was
identified in one proband). Below, we describe the WFS1 mutations
that were identified in each family and absent from 298 ethnically
matched control chromosomes, as well as the clinical manifesta-
tions. Identified polymorphisms are listed in Table IIS online. GJB2
results were negative, except in a few cases that are indicated in
Figure 1. Representative audiograms are provided in Figure 3.
Family KW200128. This is a large eight-generation family
(Fig. 1a) from Sweden with six affected individuals and is the family
described in the first report of isolated ADOA and SNHL
[Samuelson, 1940]. Four members of the family, V:2, VI:5, VI:7,
and VI:9, suffered from the same complaints, but the severity of
vision loss and hearing impairment varied among the family
members [Samuelson, 1940]. Samuelson [1940] suggested that the
cause of the reduced vision and hearing was atrophy of the optic
nerve, and the cochlear nerve, respectively.
In our follow-up study, the proband, VI:5, now deceased, had
OA from age 9 and severe bilateral SNHL from early childhood
as well as psychiatric problems (depression and hallucinations).
Furthermore, one affected family member (VII:5) committed
suicide, and four affected family members have regular psychiatric
treatment in order to cope with their anxiety. In one branch of
the family a different and unknown dominant cause of SNHL
segregated, since individuals VI:1, VII:1, and VIII:2 all had moder-
ate sensorineural hearing loss, but no visual problems and none had
the WFS1 mutation described below. GJB2 sequencing in DNA
from VII:1 was normal. Cochlear implantation was performed at
age 49, 57, and 77 years, respectively, in individuals VII:4, VI:7, and
VI:9 with variable degree of benefit. Individual VI:7 experienced
considerably improved hearing (Fig. 3), but the outcome was
questionable for the other two individuals due to old age, general
medical frailty and inability to perform relevant training efforts
after CI treatment.
The OA in the family presented with temporal paleness of the
optic nerves similar to the optic atrophy due to OPA1 mutations.
The visual impairment progressed to low visual acuity after the age
of 60, and a subsequent need for special visual adjustments
(Table III). In four of the six individuals, glaucoma developed and
responded well to standard treatment. The glaucoma treatment
may have caused a relative improvement of visual capacity due to
the optic atrophy, until late stages of the course where restriction in
visual field occurred. These family members were followed in many
instances several years ago, and details of visual acuity were not
recorded in accordance with current standards.
To establish a molecular diagnosis, DNA was collected from nine
individuals, four of whom were affected with OA and SNHL (VI:5,
VI:7, VI:9, and VII:4, Fig. 1). Since the clinical features suggested
that the disease was caused by OPA1 mutation, we first sequenced
this gene. However, no OPA1 mutation was identified. Next the
gene for Mohr–Tranebjaerg syndrome, TIMM8A, that is also
present with similar features was also sequenced, but again no
mutation was identified. Since Wolfram syndrome presents with
OA and deafness and sometimes with psychiatric problems, as in
the proband, we speculated that mutation of WFS1 might be the
cause of disease in the family. Indeed, sequencing of WFS1 in the
proband identified a heterozygous sequence change c.2051C>T in
exon 8, leading to a substitution of alanine for valine at position 684
of wolframin (p.A684V). A684 is located in the hydrophilic C-
terminus of wolframin and is conserved in evolutionarily distant
species such as mouse, rat, chicken, frog, and zebrafish (Fig. 2B).
The mutation was absent in 298 control chromosomes. These facts
along with the co-segregation of the p.A684V mutation with the
disease strongly indicate that this mutation underlies optic atrophy
and hearing loss in the family. The mutation appears to be de novo,
first manifested in affected individual V:2 who had unaffected sibs
and parents, who died in old age with preserved hearing and vision.
We then speculated whether the p.A684V WFS1 mutation
could lead to multiple mithochondrial DNA (mtDNA) deletions
since some early studies identified mtDNA deletions in Wolfram
syndrome patients [Gomez-Zaera et al., 2001] and since some
OPA1 mutations lead to multiple mtDNA deletions in skeletal
muscle [Amati-Bonneau et al., 2008]. Therefore, skeletal muscle
biopsy specimens from one p.A684V mutation carrier (VI:7) was
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analyzed for deletions of mtDNA by Southern blotting. However,
no mtDNA deletions could be detected (data not shown).
In conclusion, these data suggested that ADOA and SNHL in
the family were caused by the p.A684V mutation in WFS1.
Family NSDF916. This is a five-generation, large Caucasian
American family of English origin with 15 affected individuals
(Fig. 1b). DNA was collected from eight individuals, six of whom
were affected (III:2, III:8, III:11, IV:10, IV:12, and IV:14, Fig. 1).
The 32-year-old proband (IV:10) has had optic atrophy since
childhood and has bilateral, congenital severe to profound hearing
impairment. Sequencing of WFS1 in the proband revealed the
same heterozygous c.2051C>T mutation in exon 8 leading to the
p.A684V mutation identified in the above-mentioned Swedish
family. The mutation consistently co-segregated with optic atrophy
and hearing loss in the family. The proband was heterozygous for
the p.M34T sequence variant in GJB2, as is her father, who is deaf,
but does not have OA.
Family NSDF1272. This is a five-generation, Caucasian
American family of Polish/Russian and mixed European ancestry
with seven affected family members (Fig. 1c). DNA was available
from three individuals, of whom two were affected with optic atrophy
and hearing loss. The proband (IV:2) has optic atrophy which was
diagnosed at approximately age 30 and bilateral profound hearing
loss, which was progressive and started in early childhood.
The p.A684V mutation in WFS1 was identified in the proband
and in a remote family member (individual IV:13), who also has
bilateral OA and SNHL. In contrast, the daughter (V:1) of the
proband, has hydrocephalus, a complex medical history, bipolar
illness, and optic atrophy, but has normal hearing and does not have
the mutation. Thus, the isolated case of optic atrophy in V:1 cannot be
explained by results of WFS1 or OPA1 sequencing, suggesting that her
optic atrophy is due to another, genetic or environmental, cause.
Family NSDF2032. This is a five-generation Caucasian Ameri-
can family of Dutch ancestry with five affected individuals (Fig. 1d).
Individual IV:4 had OA diagnosed at the age of 16 years and
congenital deafness, and was found to have the p.A684V mutation
in WFS1. In addition, this individual is also homozygous for the
c.35delG mutation in GJB2. It is quite conceivable that she has two
forms of hereditary deafness given her complex family history of
deaf parents and deaf maternal grandparents.
Family NSDF1865. The proband (III:4) of this Caucasian
American family (Fig. 1e) has optic atrophy, diagnosed at age
TABLE II. Clinical Manifestations in Additional Family Members
Family NSDF916 KW010862 KW010862 KW010862
Patient ID III:2 III:2 III:5 IV:2
Inheritance ADOAþ HI ADOAþ HI ADOAþ HI ADOAþ HI
Age 69 48 42 9
Nationality US/Caucasian UK UK UK
Phenotype OAþ HI OAþ HI OAþ HI OAþ HI
WFS1 Mutation p.A684V p.G780S Not tested p.G780S
Optic atrophy
Age of onset (years) 26 Symptoms
from age 20
Diagnosed at age 42
(as a consequence
of diagnosis in IV:1)
Diagnosed at age 9
(as a consequence
of diagnosis in IV:1)
Visual acuity 20/70 (R) 20/40þ3 (R) 20/30 (R) 10/10 (R)
20/25 (L) 20/40þ2 (L) 20/30 (L) 10/10 (L)
Color vision — — Reduced —





Bilateral pallor Bilateral pallor
Hearing impairment
Age of onset (years) Congenital Congenital Congenital Congenital
Severity — Profound Profound Profound
Diabetes — — No No




Neurological abn. — No No No
Mental retardation — No No No









Normal plasma glucose Normal urine osmolality
ADOA, autosomal dominant optic atrophy; HI, hearing impairment; (—) no information; mm, millimeters of mercury.
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16, and bilateral, severe to profound sensorineural hearing loss (Fig.
3). She has also been treated for depression since the age of 38.
Sequencing of WFS1 again revealed the p.A684V mutation.
Family 81. Four members, two parents and their children,
of this Caucasian American family were analyzed (Fig. 1f). The
father (III:1) is of Dutch and Italian descent, while the mother
(III:2) is of Dutch-Polish, and German-Irish descent. III:1 is
the only relative with optic atrophy and deafness without other
manifestations of Wolfram syndrome. He had bilateral, profound
SNHL diagnosed at age 3 years and OA diagnosed at age 41 by
the ophthalmologist (M.B.M) evaluating his children. Both IV:1
and IV:2 were diagnosed with Wolfram syndrome based on
juvenile onset insulin-dependent diabetes mellitus, optic atrophy,
bilateral profound sensorineural hearing loss, and congenital
cataracts. IV:1 had hearing loss diagnosed at birth and IV:2 had
hearing loss diagnosed at age 3 months and premature birth at
30 weeks of gestation.
III:1 is heterozygous for p.A684V, and III:2 is apparently
asymptomatic and heterozygous for p.V415del mutation. Their
children, IV:1 and IV:2, are compound heterozygotes for the
WFS1 mutations p.A684V and p.V415del (c.1243_1245delGTC).
Unfortunately, neither medical data nor DNA were available
FIG. 2. (A) Representative sequence chromatograms for each of the WFS1 missense mutations compared to a normal control. The arrows indicate the
nucleotide changes of the heterozygous missense mutations. Nomenclature of mutations refers to the WFS1 RefSeq NM_006005.2, with nucleotide
numberþ1 being A of the start codon ATG. Each mutation is heterozygous in affected individuals. (B) Alignment in different species shows strong
evolutionary conservation of the relevant amino acid mutated in the patients. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com]
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FIG. 3. Pure-tone audiograms of left and right ear of representative, affected family members heterozygous for WFS1 mutation from six of the families’
studies (KW2001128 (audiograms from six individuals), NSDF916, NSDF1865, NSDF1272, and NSDF1793). For some individuals two audiograms are
shown to illustrate the hearing loss over time. Individual VI:7 (family KW200128) had cochlear implant at age 57 years, resulting in an improved
hearing between age 52 and age 68.
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from the parents of the father, III:1, and therefore it can not be
determined whether the p.A684V mutation is a de novo event
or transmitted from one of his parents. In any case, the phenotype
of the children suggest that the p.V415del mutation aggravates
the effect of the p.A684V mutation, resulting in Wolfram syndrome.
Family KW010862. This is a Caucasian UK family with six
affected individuals (Fig. 1g). DNA was available from four indi-
viduals (three affected and one unaffected). The proband (IV:1) is
reported to have bilateral, prelingual, profound hearing loss in
addition to optic atrophy. The proband has normal plasma glucose
and urine osmolality.
Sequencing of WFS1 revealed a novel heterozygous mutation,
c.2338G>A, in exon 8, which results in the substitution of a
glycine codon for a serine codon at position 780 (p.G780S). p.G780S
segregates with disease in the available family members. Furthermore,
the mutation was absent from 298 control chromosomes. Amino acid
p.G780 is located in the hydrophilic C-terminus of wolframin and is
conserved in wolframin from species such asmouse, rat, chicken, frog,
and zebrafish (Fig. 2B). Upon testing for the c.35delG mutation in
GJB2, the deaf father (Fig. 1g, III:1) of the proband was homozy-
gous, and individuals IV:1 and IV:2 were heterozygous.
Family NSDF1793. This is a small Caucasian American family
with two affected individuals (Fig. 1h). The father of the proband is
of Polish descent and her mother of Scottish descent. The proband
(III:1) had hearing loss first suspected at the age of 3–4 years, which
progressed to a severe to profound, sensorineural hearing loss.
FIG. 3. (Continued)
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Optic atrophy was recognized at approximately age 20 years. The
proband had normal mental and intellectual status.
Sequencing of WFS1 in the proband revealed a novel heterozy-
gous mutation c.2389G>T in exon 8. The mutation results in
substitution of an aspartic acid codon for a tyrosine codon at
position 797 (p.D797Y). The affected mother of the proband is also
heterozygous for this mutation. The mutation was absent from 298
control chromosomes. Amino acid p.D797 is located in the hydro-
philic C-terminus of wolframin and is conserved in wolframin from
species such as mouse, rat, chicken, frog, and zebrafish (Fig. 2B).
Haplotype Analysis
Haplotype analysis was performed in family NSDF916, with the
recurrent p.A684V mutation, by using five polymorphic markers
(D4S412, D4S3023, D4S431, D4S394, and D4S403) flanking WFS1.
A common haplotype for all affected individuals was found (Fig.
4A). Marker analysis with the same five markers in probands from
the other five p.A684V families showed that one of the probands
(NSDF1272-IV:2) had allele sizes for two markers (D4S412 and
D4S3032) in common with family NSDF916, and three probands
(NSDF-2032:IV:4, NSDF1865-III:4, and Fam81-III:1) had allele
size for one marker (D4S3023) in common with family NSDF916
(Fig. 4B). However, there is no indication of one ancient shared
haplotype between these families that originate from very different
parts of the world, and it is most likely that the mutation has arisen
independently several times.
Protein Expression Analysis of Identified
Wolframin Mutations
We next performed functional expression analysis of certain of the
indentified mutations to further validate that they are pathogenic.
Thus, we transiently transfected HEK cells with plasmid expressing
myc epitope-tagged wild-type wolframin or wolframin harboring
selected mutations and analyzed the cells for the expression level of
the exogenous wolframin by immunoblotting for the myc tag. This
analysis revealed that the p.A684V and the p.V415del mutants
showed greatly and the p.G780S mutant mildly decreased protein
expression compared to wild-type wolframin (Fig. 5, upper panel).
The p.R629W mutation previously shown to confer instability to
wolframin protein, resulting in decreased protein expression and
Wolfram syndrome, was included as a positive control [Hofmann
et al., 2003]. To control for equal transfection efficiencies across the
cell populations, we immunoblotted for enhanced green-fluores-
cent protein (EGFP) that we had co-transfected together with
wolframin. As shown in Figure 5 lower panel, all samples showed
equal expression of EGFP, confirming equal transfection across all
the cell populations analyzed.
DISCUSSION
We have identified heterozygous missense mutations in WFS1 as
the cause of ADOA and SNHL in eight families. Previously, isolated
ADOA and SNHL were reported only in association with OPA1
mutations, but our present report of multiple families, supported
by the very recent report of one family [Hogewind et al., 2010],
shows that WFS1 mutations can also underlie isolated ADOA and
SNHL. Furthermore, we have discovered that a p.A684V WFS1
mutation underlies this dual sensory impairment in the original
Swedish family [Samuelson, 1940] and in five of seven additional
families suggesting that the p.A684V WFS1 mutation may in fact be
a frequent (maybe even primary) cause of isolated ADOA and
SNHL. Finally, we demonstrate that ectopic expression in HEK cells
of wolframin with the p.A684V, p.V415del, and p.G.780S WFS1
mutations, respectively, results in reduced levels of mutant wolf-
ramin as compared to wild-type wolframin, supporting the con-
clusion that these mutations are disease-causing.
Wolfram syndrome is an autosomal recessive condition with
minimal diagnostic criteria of juvenile OA and juvenile onset
diabetes mellitus. Importantly, these clinical criteria were devel-
oped prior to identification of the responsible gene, WFS1. Several
studies on families with Wolfram syndrome have been performed.
In these studies, Wolfram syndrome is in agreement with an
autosomal recessive mode of inheritance and mutations have been
identified on both alleles in Wolfram syndrome patients and
carriers of one mutation are healthy. Thus, isolated optic atrophy
and hearing loss has not to our knowledge been reported as a feature
in heterozygous carriers of these WFS1 mutations. However inter-
estingly, heterozygous carriers of WFS1 mutations may have an
increased incidence of psychiatric disorders including suicide
attempts, endogenous depression, short-term memory loss, and
anxiety (reviewed in Cryns et al. [2003]).
Our study supports recent data that a dominant form of partial
Wolfram syndrome exists with the key features of optic atrophy and
sensorineural hearing loss, not necessarily of juvenile onset. Fur-
thermore, psychiatric illness was present in family KW200128 and
family NSDF1865. A WFS1 p.E864K missense mutation has been
reported in two families with dominantly inherited deafness and
some members affected by OA and impaired glucose regulation/
diabetes [Eiberg et al., 2006; Valero et al., 2008]. In two Japanese
families, however, the p.E864K mutation only caused isolated
LFSNHL [Fukuoka et al., 2007]. Finally, most recently, a p.K836N
mutation in WFS1 has been found associated with autosomal
dominant optic neuropathy and deafness in a family with three
affected members [Hogewind et al., 2010]. Interestingly, simulta-
neously with the family described by Hogewind et al. [2010],
Fujikawa et al. [2010] published a family with 14 affected members
segregating SNHL associated with mutation of the same WFS1
amino acid, K836, but here mutated to threonine instead of an
asparagine. However, in this family, the deafness-affected individ-
uals had no OA, nor any other WFS1-associated abnormalities, such
as diabetes insipidus or mellitus (impaired glucose tolerance was
reported in an individual with no deafness and severe depression in
another with no deafness in the family, but genetic studies could not
be performed in these individuals). These findings suggest that
there may be a spectrum of phenotypes associated with WFS1 based
on differences in functional implications of the mutations, as
suggested in the review by Tranebjaerg [2008].
We found three different wolframin missense mutations
(p.A684V, p.G780S, and p.D797Y) to be associated with a domi-
nant phenotype of OA and SNHL in eight families. The causative
changes were all identified in exon 8 of WFS1, similar to the many
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known WFS1 mutations causing Wolfram syndrome or LFSNHL.
Several lines of evidence support the conclusion that they are
pathogenic, rather than rare polymorphisms. Firstly, the three
mutations were heterozygous and in perfect dominant co-segrega-
tion with optic atrophy and hearing loss. Secondly, they were absent
from 298 ethnically matched control chromosomes and from the
NCBI SNP database. Thirdly, all three mutations affect residues
evolutionary conserved in human, rat, mouse, chicken, frog, and
zebrafish wolframin (Fig. 2B), suggesting that altering these resi-
dues have deleterious consequences for the wolframin protein.
Finally, we obtained experimental evidence for this later hypothesis
by showing that the p.A684V, and to a smaller extent the p.G780S
mutation, decreased wolframin protein expression levels. It may be
noted that although the expression analysis provide strong evidence
for a deleterious effect of the mutation, it does not provide a straight
forward relationship between wolframin expression levels and seve-
rity of disease, since the p.V415del mutation caused the greatest
decrease in wolframin expression, yet was associated with a phe-
notype only in compound heterozygosity with the p.A684V muta-
tion. Furthermore, it may be noted that although the expression
data suggest that the mutations cause disease, they do not provide
evidence that they can cause dominant disease (as opposed to
recessive disease). Rather, combined with the absence of mutations
in any other known OA genes in any of our probands, these data
collectively suggest that the identified mutations act dominantly to
cause OA and SNHL. It can be speculated that the mutations cause a
FIG. 4. Haplotype analysis. (A) Haplotype analysis in Family NSDF916, harboring the p.A684V mutation, using five polymorphic markers flanking WFS1.
(B) Marker analysis with the same five markers in probands from the other five p.A684V families. A bar indicates the haplotype carrying the mutation
in those families where this could be deduced.
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misfolded wolframin protein. Part of the misfolded wolframin pool
is degraded, but the remaining pool act as dominant negative
mutants in the wolframin pathway to cause dominant disease. In
conclusion, our findings support the involvement of missense
mutations in WFS1 in an isolated autosomal dominant monogenic
form of hearing loss and optic atrophy.
Six of the eight families with ADOA and SNHL reported
here harbored the same heterozygous WFS1 mutation, p.A684V
(c.2051C>T). Haplotype analysis in p.A684V individuals
suggested that the c.2051C>T mutation arose independently in
the families studied, and may represent a mutational hotspot.
Importantly, these data open the possibility that a single, recurrent
mutation in WFS1 i.e., p.A684V, may be a common cause of isolated
ADOA and SNHL, similar to the role played by the OPA1 p.R445H
mutation in autosomal dominant optic atrophy.
Prior to our study, the p.A684V mutation had not been reported
in association with an isolated OA and hearing loss phenotype.
However, this mutation had been identified in a patient from
Italy with Wolfram syndrome [Tessa et al., 2001] (Family 3 at the
Gene Mutation and Polymorphism Database at http://
www.khri.med.umich.edu/research/lesperance_lab/wfs_delete.php).
). The Italian patient had diabetes mellitus, optic atrophy, hearing
loss, diabetes insipidus, ataxic gait and psychiatric abnormalities. In
addition to the p.A684V mutation, the patient also harbored a
c.1387delCTCT mutation. The p.A684V mutation was absent in
100 Italian control chromosomes. Unfortunately, it is not known
whether one of the parents had the p.A684V mutation in trans and
associated with impaired vision and hearing (personal feed back
from the corresponding author A. Tessa, who reported that the
parents were unavailable for follow-up). By contrast, in the present
study, DNA was available from the parents of two children (Family
81) with Wolfram syndrome, who are compound heterozygous for
p.A684V and p.V415del in WFS1. The children both have juvenile
onset of insulin-dependent diabetes mellitus, OA, bilateral pro-
found sensorineural hearing loss and congenital cataracts [Mets et
al., 2010]. Interestingly, we identified the p.A684V mutation in
heterozygous state in the father, who has OA and hearing loss only,
while the mother, heterozygous for the p.V415del mutation, had no
symptoms. These data support that heterozygosity for p.A684V
alone causes isolated OA and hearing loss. Since the mother had no
obvious disease symptoms, we went on to demonstrate that the
p.V415del mutation greatly decreased wolframin protein expres-
sion. This demonstrates that the p.V415del alteration is indeed the
responsible mutation that aggravates the effect of the p.A684V
mutation, causing Wolfram syndrome in the children. We believe
that a similar scenario also underlies the Wolfram syndrome
phenotype of the Italian patient reported by Tessa et al. [2001],
although his parents would have to be mutation analyzed to
substantiate this conclusion.
The current lack of knowledge about the physiological and
cellular and biochemical functions of wolframin makes it difficult
to explain the disease-causing mechanism of the mutations. To this
end, we addressed whether WFS1 mutations could lead to multiple
mitochondrial DNA deletions, by analyzing one p.A684V patient
for deletions of mtDNA in skeletal muscle. However, no deletions
were detected suggesting that the p.A684V mutation does not
cause ADOA and hearing loss by increasing mtDNA instability.
Unfortunately, muscle DNA was not available from the other
patients presented here.
Till date, only mutations in OPA1 have been repeatedly linked to
the rare phenotype featuring isolated OA with sensorineural deaf-
ness. One recurrent OPA-1 mutation, the heterozygous p.R445H
missense mutation, underlies the large majority of reported cases of
isolated OA and hearing loss. This mutation was first identified in
a Japanese and a French patient [Amati-Bonneau et al., 2003;
Shimizu et al., 2003] and subsequently in families from the US,
and Belgium [Payne et al. 2004] and finally in five patients/families
from France, Spain, and of Caucasian origin [Amati-Bonneau et al.,
2005; Li et al., 2005]. In a few of these families, some patients also
developed ptosis, ophthalmoplegia, ataxia, and/or nonspecific
myopathy at middle age [Payne et al., 2004; Yu-Wai-Man et al.,
2010]. Only two other OPA1 mutations (c.970delCGTTCTCCA
and p.G401D) have so far, to our knowledge been associated with
isolated OA and hearing loss [Puomila et al., 2005; Ke et al., 2006;
Amati-Bonneau et al., 2009]. Phenotypic characteristics of most of
these patients include onset of hearing loss at the age of 6–30 years
[Amati-Bonneau et al., 2005]. In contrast, all probands with WFS1
mutation ascertained in the present study were congenitally deaf or
had hearing loss onset in early childhood (Table I). Further patients
need to be studied to evaluate whether WFS1 mutation, and in
particular the p.A684V mutation, is a predominant cause of
dominant OA and SNHL, and whether there is a correlation
between early onset of hearing loss and WFS1 mutation versus
OPA1 mutation, to assist in molecular diagnosis of this disease.
The fact that carriers of WFS1 mutations associated with Wol-
fram syndrome do not have hearing impairment and usually not
significant if present, and the previous reports of heterozygosity for
other WFS1 mutations resulting in nonsyndromic autosomal
dominant LFSNHL emphasize the difficulties in predicting the
consequences of the different types of WFS1 mutations [Eiberg et
al., 2006; Tranebjaerg, 2008]. Our report supports this notion, since
our study is the first study of several families with OA and hearing
loss without other major clinical features (two families did have
psychiatric abnormalities when carefully followed) found to be
associated with mutations in WFS1. The first family segregating
optic atrophy and hearing loss in a dominant pattern with a WFS1
mutation (p.E864K) was described by Eiberg et al. [2006]. However,
FIG. 5. Functional protein expression analysis of WFS1 mutations.
HEK293 cells were co-transfected with plasmid expressing myc-
tagged wild-type or mutant wolframin together with plasmid
expressing EGFP. The cells were lysed 16 hr post-transfection and
the cell extracts were subjected to SDS-PAGE and immunoblotting
for the myc tag and EGFP. The experiment was repeated three
times with independently generated mutants with similar results.
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in this family, careful metabolic evaluations of three out of four
mutation carriers, revealed that they had undiagnosed diabetes,
impaired glucose tolerance, and/or impaired insulinogenic index
indicating that the p.E864K mutation may affect pancreatic beta-
cell function as well [Eiberg et al., 2006]. It is entirely possible that
additional abnormalities are actually present in a higher fraction of
the families with WFS1 related disorder, as illustrated by psychiatric
disease in the two families in the present report (KW200128 and
NSDF1865) and reported by Eiberg et al. [2006] and Valero et al.
[2008]. A similar modification of clinical presentation became
evident when OPA1 patients in larger numbers were carefully
clinically examined, showing that about 20% actually turned out
to have neurological abnormalities [Yu-Wai-Man et al., 2010].
In several of our families there are several spouses with SNHL,
who may introduce one or more additional SNHL genes. It can,
therefore, be speculated that these genes may contribute to the
phenotype or are acting digenically with the identified WFS1
mutation in the respective families. In all cases, where we have
both phenotypic and molecular genetic results and found a hetero-
zygous missense mutation in WFS1, the OA and SNHL phenotype
was present, pointing to that the respective WFS1 mutations
alone are capable of causing the disease phenotype. However, in
one family (NSDF2032) the proband is congenital deaf, and in
addition to being heterozygous for the p.A864V mutation in WFS1,
this individual is homozygous for the c.35delG mutation in GJB2.
Thus, in this case, it cannot be solved which of the two genes is
causing her deafness.
In conclusion, we fully support the recent suggestion by Valero et
al. [2008] of systematic sequencing analysis of WFS1 in patients
with diabetes and deafness (þ/ optic atrophy), in particular when
mtDNA mutations have been excluded, and a broad clinical
examination in such patients. We also recommend WFS1 sequenc-
ing in patients with optic atrophy and early onset hearing loss,
especially when OPA1 mutations have been excluded [Tranebjaerg,
2008]. Hopefully, future WFS1 screening of larger patient cohorts
with hearing loss and optic atrophy will determine the extent to
which WFS1 mutations underlies this phenotype. Finally, supple-
mentary efforts are essential to determine the precise functions of
wolframin in the inner ear and eye and the role of genetic or
environmental modifying factors. Studies focusing on the func-
tional consequences of WFS1 mutations identified in patients are
needed and may help to resolve why different WFS1 mutations may
cause either recessive Wolfram syndrome, dominant LFSNHL or
dominant optic atrophy with deafness, respectively, which would
have major implications for the involved families in terms of appro-
priate genetic counseling and relevant clinical long-term follow-up.
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